Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.
Research context
Joinn Laboratories (China) Co.,Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Joinn Laboratories (China) Co.,Ltd is currently in a long term uptrend where the price is trading 17.5% above its 200 day moving average.
From a valuation standpoint, the stock is 226.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 31.4.
Joinn Laboratories (China) Co.,Ltd's total revenue rose by 52.8% to $444M since the same quarter in the previous year.
Its net income has increased by 93.1% to $197M since the same quarter in the previous year.
Finally, its free cash flow grew by 578.2% to $177M since the same quarter in the previous year.
Based on the above factors, Joinn Laboratories (China) Co.,Ltd gets an overall score of 4/5.